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HEALTH CARE COSTS AND RESOURCE USE IN PATIENTS
WITH MAJOR DEPRESSIVE DISORDER:A COMPARISON
BETWEEN ESCITALOPRAM AND OTHER ANTIDEPRESSANTS
Wu E1,Yang E1, Greenberg P1, Erder H2,Yu AP1, Buesing M1
1Analysis Group, Inc, Boston, MA, USA, 2Forest Research Institute,
Jersey City, NJ, USA
OBJECTIVES: To compare the health care costs and utilization
of adult major depressive disorder (MDD) patients treated 
with escitalopram to those treated with other SSRI/SNRI.
METHODS: MDD patients (age ≥ 18) initiated on escitalopram
or other SSRI/SNRI were identiﬁed in the IHCIS National
Managed Care Database (2003–2005). Health care costs and
resource use of patients on escitalopram were compared to
patients on other antidepressants over the 6 months following
therapy initiation (study period). Wilcoxon tests were used to
compare costs descriptively. GLM regressions with log link func-
tion were used for cost comparison. Two-part regression models
were used to deal with zero cost. Logistic regressions were used
to compare 6-month rates of hospitalization, emergency visit,
and substance abuse. Negative binomial regressions were used
to compare the number of hospitalization days and emergency
visits. All regressions adjusted for patient demographics, comor-
bidities, and baseline medical resource use. Costs were inﬂation
adjusted to 2005 US dollars. RESULTS: The study sample
included 10,465 MDD patients initiated on escitalopram and
28,310 patients initiated on other SSRI/SNRI. Descriptive analy-
ses showed that escitalopram patients had on average $753
lower 6-month total health care costs than patients on other
SSRI/SNRI (p < 0.0001), with more than half of the difference
from lower hospitalization costs ($394, p < 0.0001). GLM
regressions showed that escitalopram patients cost $839 less (p
< 0.0001) in total health care costs and $405 less (p < 0.01) in
inpatient costs. Medical resource utilization regressions showed
that, compared to patients on other SSRI/SNRI, patients on esc-
italopram were less likely to have hospitalization (p = 0.0001),
emergency visit (p < 0.0001), and substance abuse (p = 0.001).
Escitalopram patients had 31% fewer hospitalization days (p <
0.0001) and 15% fewer emergency visits (p < 0.0001). CON-
CLUSION: Compared to adult MDD patients initiated on other
SSRI/SNRI, patients on escitalopram have lower health care
costs and utilize fewer medical resources.
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ECONOMIC EVALUATION OF LONG ACTING TREATMENTS
FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN THE
MILITARY HEALTH SYSTEM
Devine JW, Moore E,Tiller KW,Trice S, Meade DJ, Lawrence JB
Department of Defense Pharmacoeconomic Center, Fort Sam
Houston,TX, USA
OBJECTIVES: To evaluate the cost-effectiveness of frequently
used long acting treatments for children and adolescents with
attention-deﬁcit/hyperactivity disorder (ADHD) in the U.S. Mil-
itary Health System (MHS). METHODS: A decision analytic
model compared the cost-effectiveness of three commonly used
long acting treatments for ADHD in the MHS (methylphenidate
OROS, mixed amphetamine salts extended-release, and atom-
oxetine) to treatment with methylphenidate immediate-release
(MPH IR) over a one year time horizon. Inputs for model para-
meters were derived from published literature. Treatment efﬁ-
cacy was estimated from a mixed treatment comparison model
of published randomized controlled trials with response to treat-
ment deﬁned as either very much improved or much improved
on the physician-rated Clinical Global Impression of Improve-
ment scale. Health care costs were measured from a MHS per-
spective in dollars and drug costs were based on Federal Supply
Schedule prices. Treatment outcomes were measured in quality-
adjusted life-years (QALYs). The model considered two scenar-
ios. One of equal patient preference for response to treatment
and another that assumed a greater preference for response with
extended-release and non-stimulant products compared to MPH
IR. Model uncertainty was evaluated with probabilistic sen-
sitivity analyses and cost-effectiveness acceptability curves.
RESULTS: Under a scenario of equal patient preferences,
methylphenidate OROS was slightly more effective than MPH
IR with an estimated incremental cost-effectiveness ratio (ICER)
of $111,536/QALY. Greater patient preference for extended-
release and non-stimulant products increased the estimated
beneﬁt of the long acting treatments. This improvement lowered
the ICER for methylphenidate OROS to $27,214/QALY com-
pared to MPH IR. Atomoxetine was also on the cost-effective-
ness frontier at an additional cost of $34,239/QALY compared
to treatment with methylphenidate OROS. Under both scenar-
ios, mixed amphetamine salts extended-release was dominated
by methylphenidate OROS. CONCLUSION: Long acting treat-
ments for ADHD in the MHS were cost-effective at commonly
accepted thresholds only under a scenario that assumed greater
patient preference for response to these products.
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36-MONTH COST-UTILITY ANALYSIS OF ANTIPSYCHOTIC
TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE
PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT
HEALTH OUTCOMES) STUDY
Windmeijer F1, Brown J2, Novick D2, Hong J3, Knapp M3,
Kontodimas S2, Ratcliffe M2
1University of Bristol, Bristol, UK, 2Eli Lilly and Company Limited,
Windlesham, Surrey, UK, 3London School of Economics, London, UK
OBJECTIVES: To determine the cost-effectiveness (measured
using an incremental cost-utility ratio) of treating schizophrenia
patients with olanzapine versus risperidone, clozapine, quetiap-
ine, amisulpride, oral typical and depot typical antipsychotics.
METHODS: European SOHO is a 3-year, prospective, outpa-
tient, observational study associated with antipsychotic treat-
ment in 10 European countries. Health care resource use and
quality of life data (EuroQol EQ-5D and UK population utility
values) were collected at baseline, 3, 6, 12, 18, 24, 32 and 36
months. UK health care costs were applied to the resource use
data for the 10 countries. Pair-wise incremental costs and utili-
ties were estimated between olanzapine-treated patients and
patients treated with each of the other antipsychotics. Utility
increments were used to estimate quality-adjusted life-years
(QALYs) gained. Incremental cost-utility ratios were expressed
as the additional cost per QALY gained. Bootstrap replications
provided an estimate of uncertainty. RESULTS: 10,972 patients
were enrolled at baseline, 65% were eligible for analyses at 36
months. Treatment with olanzapine is more effective and less
costly than clozapine and quetiapine. Treatment with olanzap-
ine is more effective but more costly compared to treatment with
risperidone, amisulpride, and oral typical or depot typical
antipsychotics. The incremental cost-utility ratios of olanzapine
versus these four medications were £12,343, £1586, £14,849
and £23,379 per additional QALYs gained respectively. The
bootstrap replications for uncertainty showed that 100% of 
the replications fell below a £30,000 per QALY threshold in the
comparison with quetiapine and oral typicals. It was 98%, 91%,
99% and 79% for the comparison with risperidone, clozapine,
amisulpride and depot typicals respectively. CONCLUSION:
Among SOHO patients, if a funding threshold of £30,000 per
QALY gained is assumed, olanzapine has a high probability of
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being the most cost-effective treatment compared with atypical,
oral and depot typical antipsychotic medications.
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PREDICTORS OF BIPOLAR DISORDER IN PATIENTS
DIAGNOSED WITH MAJOR DEPRESSION IN A PRIVATELY
INSURED POPULATION
Kamat S1, Rajagopalan K2, Pethick N2,Willey VJ1
1HealthCore, Inc, Wilmington, DE, USA, 2AstraZeneca Pharmaceuticals
LP, Wilmington, DE, USA
OBJECTIVES: To investigate whether patients with bipolar dis-
order (BD) who are misdiagnosed with major depressive disor-
der (MDD) can be identiﬁed through claims data-based predictor
variables. METHODS: Administrative claims data from 3 US
health plans were used to identify patients diagnosed with MDD
between January 1, 2000 through March 31, 2004. An age-,
gender-, and region-stratiﬁed random sample of patients with
°Ã2 medical claims for MDD and none for BD was surveyed 
via telephone to complete the Mood Disorder Questionnaire
(MDQ), a tool used to screen patients for BD symptoms. Uni-
variate logistic regression, followed by multivariate techniques,
was used to identify predictors of BD. Baseline variables with a
univariate p-value <0.10 were entered into the ¢®°Æbest-ﬁt¢®±
multivariable model with acceptable predictive validity for ﬁnal
predictor variable selection. RESULTS: From a sampling frame
of 41,738 patients diagnosed with MDD, based on sample size
calculations, surveys were administered until a target sample of
1360 patients was screened. Screened BD positive patients (n =
94, 6.9%) were considered likely to be inaccurately diagnosed.
A higher percentage of males screened positive compared to
females (8.6% vs 6.1% respectively, P = 0.092) and patients aged
18–35 were 3 times more likely to screen positive than patients
56 years and above (P < 0.01). Rates of inpatient or ER visits
related to mental health conditions were higher in patients
screening positive compared to patients screening negative for
BD (40.4% vs 21.3%, P < 0.01). The ﬁnal model indicated that
age, gender, rate of inpatient or ER visits related to mental health
conditions, substance abuse, concomitant use of anticonvulsants,
antidepressants, antipsychotic medications, and anxiolytic
agents are useful predictors in identifying BD patients who are
diagnosed inaccurately with MDD. CONCLUSION: These
claims data-based predictor variables, after necessary validation
and reliability checks, can be used by health plans in identifying
patients at high risk of missed BD diagnosis.
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ACCESS TO ILLICT DRUGS: POLICY IMPLICATIONS FROM
THE 2003 NATIONAL SURVEY
Lee D
Cleveland State University, Cleveland, OH, USA
OBJECTIVES: To examine whether perceived access to illicit
drugs by occupation is consistent with acutual drug use.
METHODS: We used data from a 2003 National Survey on
Drug Use and Health. A total of 55,245 Americans aged 12 and
older participated in the study. Of those 55,245 study partici-
pants, 29,915 subjects who are currently employed were selected
for this present study. Descriptive analyese (ANOVA and chi-
square test) and regression modeling were performed to detect
the difference between illict drug use and occupation. RESULTS:
The majority of the sample was white (70%) and half of the
sample was male (56%). About 44% of the sample was between
the ages of 18 and 25. Of the 5 illicit drugs, marijuana was found
to be easiest to access, followed by cocaine, crack, LSD, and
heroin. Protective service workers reported having the easiest
access to all ﬁve substances, followed by sales occupations. Com-
pared to other occupations, workers in entertainment, sports,
media, and communications reported having relatively easy
access to marijuana and LSD. Protective service workers were
the best predictor of easy access to all ﬁve illict drugs. CON-
CLUSION: Inconsistency was found that protective service
workers had an easy access to drugs but their actual usage of
illicit drugs was very low. Other policy implications relating to
access to drugs by occupations were addressed in the study.
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STIMULANT UTILIZATION IN CHILDREN UNDER A STATE
EMPLOYEES BENEFIT PROGRAM
Gardner SF, Stowe CD
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: We analyzed prescribing patterns for ADD treat-
ment among children of Arkansas state employees and public
school employees (primarily elementary and secondary teachers)
in order to determine if differences existed based on age, gen-
der, type of stimulant prescribed, and medication dosage.
METHODS: This observational study utilized administrative
claims from a state employees’ database in 2005. The popula-
tion consisted of children (less than 19 years) with a diagnosis
of ADD with or without hyperactivity. RESULTS: 1100 children
(3.6%) in the claims database (30,821 children 3 to 18 years)
had a diagnosis of ADD with or without hyperactivity, and
received at least one medication during 2005. Two sample pop-
ulations were examined: children of state employees (ASE) and
public school employees (PSE). 3.1% of children in both data-
bases (PSE = 499/16,102, ASE = 450/14,719) received at least
one stimulant. Mean age of children in the ASE (69.6%) was
11.2 years, ±3.6, and in the PSE (69.3% male) was 11.7 years,
±3.7. The most commonly prescribed stimulants were Adderall
(n = 220) and Concerta (n = 424). The dosage range for Adder-
all was 5 to 80 mg, and 18 to 144 mg for Concerta. There was
a positive correlation (p < 0.001) between age and Adderall
dosage (R = 0.36) and between age and Concerta dosage (R =
0.29). Dosages above the recommended maximum were seen in
7.7% of PSE and 4.9% of ASE children. CONCLUSION: Chil-
dren of ASE were equally likely as children of PSE to be treated
with stimulants for ADD, although there was a trend toward
higher dosages in the children of PSE.
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